Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Operating Expenses: 2016-2024

Historic Operating Expenses for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $147.5 million.

  • Akebia Therapeutics' Operating Expenses rose 25.61% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.0 million, marking a year-over-year increase of 11.76%. This contributed to the annual value of $147.5 million for FY2024, which is 11.55% down from last year.
  • Akebia Therapeutics' Operating Expenses amounted to $147.5 million in FY2024, which was down 11.55% from $166.7 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Operating Expenses ranged from a high of $376.0 million in FY2020 and a low of $147.5 million during FY2024.
  • Moreover, its 3-year median value for Operating Expenses was $166.7 million (2023), whereas its average is $200.6 million.
  • Data for Akebia Therapeutics' Operating Expenses shows a maximum YoY slumped of 42.05% (in 2023) over the last 5 years.
  • Akebia Therapeutics' Operating Expenses (Yearly) stood at $376.0 million in 2020, then fell by 13.43% to $325.5 million in 2021, then fell by 11.61% to $287.7 million in 2022, then slumped by 42.05% to $166.7 million in 2023, then dropped by 11.55% to $147.5 million in 2024.